Supporting Materials Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country Phase 1/2a expansion cohort 20.3 MB Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: results from a multi-center multi-country Phase 1/2a expansion cohort 6.6 MB
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country Phase 1/2a expansion cohort 20.3 MB
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: results from a multi-center multi-country Phase 1/2a expansion cohort 6.6 MB
